U rinary incontinence affects more than 13 million women in the United States and has been associated with profound adverse effects on quality of life 1, 2 ; an increased risk of falls, fractures, 3 and nursing-home admissions 4 ; and more than $20 billion in estimated annual direct health care costs. 5 Observational studies suggest that obesity is a strong risk factor for urinary incontinence, [6] [7] [8] [9] and preliminary studies suggest that weight loss may have a beneficial effect on urinary incontinence in obese patients. [10] [11] [12] [13] [14] Reductions in urinary incontinence have been observed in morbidly obese women who have had dramatic weight loss after bariatric surgery. [11] [12] [13] In a small cohort study of overweight and obese women with incontinence, those who had a weight loss of more than 5% had a reduction of at least 50% in the frequency of incontinence (P = 0.03). 14 A 3-month study reported that overweight and obese women randomly assigned to a very-low-calorie liquid diet had a significantly greater decrease in the weekly number of urinary-incontinence episodes than those assigned to no intervention. 10 We conducted a randomized, clinical trial, the Program to Reduce Incontinence by Diet and Exercise (PRIDE), to determine whether a behavioral weight-reduction intervention for overweight and obese women with incontinence would result in greater reductions in the frequency of incontinence episodes at 6 months as compared with a control group.
Me thods

Participants
We recruited 338 women between July 2004 and April 2006 in Providence, Rhode Island, and Birmingham, Alabama. Women were eligible for the study if they were at least 30 years of age, had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 25 to 50, and at baseline reported 10 or more urinary-incontinence episodes in a 7-day diary of voiding. The participants were required to monitor their food intake and physical activity for 1 week, to be able to walk unassisted for two blocks (approximately 270 m) without stopping, and to agree not to initiate new treatments for incontinence or weight reduction for the duration of the study. Previous medical therapy for incontinence or obesity did not affect eligibility. Exclusion criteria included use of medical therapy for incontinence or weight loss within the previous month, current urinary tract infection or four or more urinary tract infections in the previous year, a history of incontinence of neurologic or functional origin (due to factors not involving the lower urinary tract, such as chronic impairment of physical or cognitive functioning), previous surgery for incontinence or urethral surgery, major medical or genitourinary tract conditions, pregnancy or parturition in the previous 6 months, type 1 or type 2 diabetes mellitus requiring medical therapy that increased the risk of hypoglycemia, and uncontrolled hypertension.
The study was approved by the institutional review board at each site, and written informed consent was obtained from all participants before enrollment. Slim-Fast, a meal-replacement product, was donated by the manufacturer, Unilever, which had no role in trial design, data accrual, data analysis, or preparation of the manuscript. The biostatistician authors at the University of California, San Francisco, vouch for the completeness and accuracy of the data.
Study Design
Eligible participants were randomly assigned at a 2:1 ratio to an intensive 6-month behavioral weight-loss program or to a structured four-session education program (the control group). Randomization was performed with the use of randomly permuted blocks of three or six, stratified according to clinical center, with random assignment concealed in tamper-proof envelopes. The participants were aware of their treatment assignment, but the staff members who collected the outcome data were not.
The participants completed questionnaires concerning their demographic characteristics, medical and behavioral history, and history of incontinence that were routinely used by the investigators. The participants were weighed to the nearest 0.5 kg on a calibrated digital scale (Tanita BWB 800) while wearing street clothes and without shoes. Height was measured at baseline to the nearest centimeter with the use of a calibrated, wall-mounted stadiometer and a horizontal measuring block.
The participants were trained to complete a 7-day diary of voiding (see the Supplementary Appendix, available with the full text of this article at NEJM.org), and interviewers reviewed the diaries with the participants to answer questions and reconcile inconsistencies. 15, 16 The partici-pants recorded the time of each void and each incontinence episode. According to the instructions provided, the participants identified each episode as stress incontinence (involuntary loss of urine with coughing, sneezing, straining, or exercise), urge incontinence (loss of urine associated with a strong need or urge to void), or other. For the purposes of analysis, each woman was then classified as having stress-only incontinence, stress-predominant incontinence (i.e., at least two thirds of the total number of episodes were stress episodes), urge-only incontinence, urge-predominant continence (i.e., at least two thirds of the total number of episodes were urge episodes), or mixed incontinence (i.e., at least two types were reported, but no type constituted two thirds of the total number of episodes).
Study Groups
At randomization, all participants were given a self-help behavioral-treatment booklet with instructions for improving bladder control. 17 The booklet provided basic information about incontinence, how to locate pelvic-floor muscles and how to perform daily exercises with them, how to use pelvic-floor muscles to avoid stress incontinence, and how to control urinary urgency, as well as instructions on completing voiding diaries. Incontinence was not discussed further in either the control group or the weight-loss group.
Women assigned to the control group were scheduled to participate in four education sessions at months 1, 2, 3, and 4. During these 1-hour group sessions, which included 10 to 15 women, general information was presented about weight loss, physical activity, and healthful eating habits, according to a structured protocol.
The weight-loss program was designed to produce an average loss of 7 to 9% of initial body weight within the first 6 months of the program and was modeled after that used in the following two large clinical trials: Look AHEAD (Action for Health in Diabetes), 18,19 a lifestyle intervention trial intended to achieve and maintain weight loss in patients with diabetes, and the Diabetes Prevention Program. 20 The participants in the weightloss program met weekly for 6 months in groups of 10 to 15 for 1-hour sessions that were led by experts in nutrition, exercise, and behavior change and were based on a structured protocol. The participants were given a standard reduced-calorie diet (1200 to 1500 kcal per day), with a goal of providing no more than 30% of the calories from fat. To improve adherence, the participants were provided with sample meal plans and were given vouchers for a meal-replacement product (SlimFast) to be used for two meals a day during months 1 to 4 and for one meal a day thereafter.
The participants were encouraged to gradually increase physical activity (brisk walking or activities of similar intensity) until they were active for at least 200 minutes each week. Behavioral skills, including self-monitoring, stimulus control, and problem-solving, were emphasized.
Outcomes
The primary outcome measure was the percentage change in the number of incontinence episodes reported in the 7-day voiding diary at 6 months after randomization. 15, 16 Secondary outcome measures included the percentage change in the number of episodes of urge and stress incontinence; the proportion of women in whom the frequency of incontinence decreased by at least 50%, 70%, or 100%; and change in a validated measure of participant satisfaction with incontinence treatment (assessed with the use of Likert scales of perceived change in frequency of incontinence, volume of urine loss, the degree to which incontinence is a problem, and satisfaction with the change in incontinence at 6 months). 21 In addition, 24-hour involuntary urine loss at baseline and 6 months was determined by a pad test standardized by the International Continence Society. 22 Preweighed urinary-incontinence pads were used for 24 hours and returned by the participants in sealed plastic bags, and the amount of urine lost was measured by weighing the pads.
Statistical Analysis
We estimated that 330 women would need to be enrolled to detect a net reduction in incontinence frequency of six episodes per week after 6 months; this reduction was half the effect seen in a pilot study 10 but was large enough to be clinically meaningful. This estimate allowed for a 10% rate of attrition at 6 months and assumed imputation of missing data for 6-month outcomes. In addition, we assumed that correlation of outcomes within the small intervention groups would result in a 25% increase in the required sample size.
We compared the two groups in terms of baseline demographic and clinical characteristics, accounting for potential correlation among the women in each new "wave" (a wave consisted of one control group and two weight-loss groups)
The who were beginning treatment. Chi-square tests were used to compare the proportion of missing 6-month data according to treatment group. To assess the effects of treatment on the frequency of incontinence, we used generalized estimating equations with negative binomial models, with adjustment for clinical site and the baseline and 6-month outcomes treated as repeated measures. In a sensitivity analysis, we also used the nonparametric Wilcoxon rank-sum test to compare percentage changes in the frequency of incontinence. The effects of treatment on the percentage change in weight from baseline to 6 months were assessed with the use of linear mixed models adjusted for site.
Attrition in weight-loss studies commonly masks regained weight. To address this potential source of bias, we used multiple-imputation methods to impute missing weight data at 6 months, on the assumption of no change from baseline on average among dropouts. In addition, we imputed missing data on incontinence frequency at 6 months and pad weight for participants in both groups as if they had been assigned to the control group, in which the average weight loss was minimal but some reduction in incontinence frequency was observed. We also performed a complete-case analysis without imputation of missing outcomes.
The proportions of women with reductions of 50%, 70%, and 100% in the frequency of incontinence were compared by generalized estimating equations, with the use of logistic models with robust standard errors. We focused on a 70% reduction in incontinence frequency, because this figure has been reported as a threshold for improvement in patient satisfaction. 21 R esult s
Baseline Characteristics
Of the 2116 participants screened by telephone, 1778 were excluded during screening and 338 underwent randomization (Fig. 1) . The characteristics of the participants in the weight-loss and control groups were similar at baseline ( The mean (±SD) age was 53±11 years; 19% were black. The mean BMI (36±6) and the total number of incontinence episodes per week (24±18) ( Table 2) were similar in the two groups. At baseline, 297 women had at least one episode of stress incontinence and 320 women had at least one episode of urge incontinence per week. In both groups, urge-related incontinence was more common than stress-related incontinence.
Follow-up
At the 6-month follow-up assessment, 318 women (94.1%) provided weight data (97.8% of the women in the weight-loss group and 86.6% of those in the control group, P<0.001) (Fig. 1 type of incontinence, frequency of incontinence episodes, and pad weight were not significantly associated with the retention of participants at 6 months.
Weight Loss
At the 6-month visit, the women in the weightloss group had a mean loss of 8.0% of body weight from baseline (95% confidence interval [CI], −9.0 to −7.0; mean loss, 7.8 kg), as compared with 1.6% (95% CI, −2.7 to −0.4; mean loss, 1.5 kg) among women in the control group (P<0.001) ( Table 2) . The results were similar in analyses adjusted for baseline weight and in sensitivity analyses performed with the use of complete-case methods (the mean loss was 8.2% in the weightloss group and 1.8% in the control group, P<0.001).
Urinary Incontinence
After 6 months, women in the weight-loss group had a mean decrease in the total number of incontinence episodes per week of 47.4% (95% CI, −54.0 to −39.9), as compared with 28.1% in the control group (95% CI, −40.9 to −12.6; P = 0.01) ( Table 2) . The results were similar in analyses performed with the use of complete-case methods (the mean decrease in the total number of incontinence episodes per week was 49.1% in the intervention group and 34.0% in the control group, P = 0.01) and nonparametric tests (P = 0.003 by the Wilcoxon rank-sum test). The reduction in the number of urinary-incontinence episodes from baseline was attributable primarily to a reduction in episodes of stress incontinence (a decrease of 57.6% in the intervention group as compared with 32.7% in the control group, P = 0.02; P<0.001 0.14 * Plus-minus values are means ±SD and were calculated with the use of multiply imputed data sets for body weight and frequency of urinary-incontinence episodes. † Percentage changes and P values for the comparison between the weight-loss group and the control group were calculated with the use of multiply imputed data sets and mixed linear regression models, with control for clinical site and correlation of outcomes in the intervention groups. The data sets for body weight were based on 221 women in the weight-loss group and 97 in the control group for whom data were available at baseline and 6 months. ‡ Percentage changes and P values for the comparison between the weight-loss and the control groups were calculated with the use of multiply imputed data sets and negative binomial models, with control for clinical site and correlation of outcomes in the intervention group. The data sets for urinary incontinence were based on 214 women in the weightloss group and 90 in the control group for whom data were available at baseline and 6 months. by the Wilcoxon rank-sum test). Although the average decrease in the frequency of episodes of urge incontinence was larger in the weight-loss group than in the control group (42.4% vs. 26.0%), this difference was not statistically significant (P = 0.14; P = 0.16 by the Wilcoxon rank-sum test). The effect of treatment on the total number of incontinence episodes per week was similar among subgroups classified at baseline as having stress or stress-predominant incontinence, urge or urgepredominant incontinence, or the mixed type of incontinence (P = 0.75 by a test for heterogeneity). A higher proportion of women in the weightloss group than in the control group had a reduction of at least 70% in the total number of incontinence episodes per week (P<0.001) (Fig. 2) . This pattern was also observed for both stress incontinence and urge incontinence (P = 0.009 and P = 0.04, respectively) (Fig. 3) . The results were similar after analysis by complete-case methods.
No differences were reported between the intervention and control groups in the use of behavioral techniques presented in the self-help incontinence booklet. About one third of the women in both groups reported using urge-suppression techniques or doing pelvic-floor exercises at least weekly, and three quarters of the women found the booklet helpful (P>0.20 for all comparisons). In exploratory analyses, we assessed potential correlates of a decrease in urinary incontinence in the control group. We found moderate associations with weight loss and physical exercise (P = 0.11 and P = 0.05, respectively) but no evidence for an effect of pelvic-floor exercises.
There was no significant change from baseline in either group and no difference between treatment groups in daytime or nighttime voiding frequency. Involuntary urine loss during a 24-hour period, as measured by an increase in pad weight, decreased significantly from baseline, by 45% in the weight-loss group and by 34% in the control group, but the difference between the groups was not statistically significant (P = 0.23).
Satisfaction with and Perception of Treatment
As compared with women in the control group, women in the weight-loss group perceived a greater decrease in the frequency of urinary-incontinence episodes and a lower volume of urine loss. They also regarded incontinence as less of a problem and reported higher satisfaction with the change in their incontinence at 6 months (P<0.001 for all comparisons) (Table 3) .
Discussion
Among overweight and obese women with urinary incontinence, the comprehensive behavioral weight-loss program in this study resulted in a significantly greater reduction in the frequency of self-reported urinary-incontinence episodes at 6 months as compared with the structured education program. A higher proportion of women in the weight-loss group than in the control group reported a clinically meaningful reduction of at least 70% in the total weekly number of episodes of any incontinence, stress incontinence, and urge incontinence. In addition, the women in the weight-loss group perceived greater improvement in their incontinence and were more satisfied with their improvement. The 8% reduction in weight achieved in this study slightly exceeded the 6-month weight loss among participants in the lifestyle-intervention subgroup of the Diabetes Prevention Program (7%) 18 and approximated the 1-year weight losses in the Look AHEAD trial, 23 on which the current intervention was modeled. These trials suggest that behavioral weight-loss programs can consistently produce initial weight losses of this magnitude.
Both stress incontinence and urge incontinence were reduced more in the weight-loss group than in the control group, but the difference between the groups was significant only for stress incontinence. However, there was no interaction between treatment and type of incontinence, a result suggesting that the difference in treatment effects between the subgroup of women with urge incontinence and the subgroup with stress incontinence may have been due to chance. In addition, the proportion of women reporting a clinically meaningful decrease in the number of incontinence episodes per week of 70% or more was greater in the intervention group than the control group for all incontinence episodes, urge-incontinence episodes, and stressincontinence episodes. This result suggests that overweight or obese women with stress, urge, or mixed incontinence may benefit from weight loss.
Previous studies that have reported significant reductions in incontinence after weight reduction provide information on possible mechanisms by which reduction in incontinence occurs. 10, 11, 14 It has been hypothesized that obesity may contribute to urinary incontinence because of the increase in intraabdominal pressure due to central adiposity, which in turn increases bladder pressure and urethral mobility, exacerbating stress incontinence and possibly urge incontinence. 10, 11, 24, 25 Weight reduction may reduce forces on the bladder and pelvic floor, thus reducing incontinence. Positive effects of the weight-loss intervention on incontinence may also have resulted from changes in dietary intake and physical activity. The frequency of incontinence episodes decreased by about 28% in the control group. This reduction is consistent with reports from trials of other interventions for incontinence and is probably due to regression to the mean and heightened awareness of bladder habits among participants, which may result from completing voiding diaries and questionnaires. The booklet describing behavioral approaches to the control of incontinence has been shown to be effective 26, 27 and, in combination with four group-education sessions about diet and exercise, may have contributed to improvement in the control group.
The primary outcome measure in our study was change in self-reported incontinence episodes as recorded in the 7-day voiding diary. This is the most common outcome measure in nonsurgical intervention trials for urinary incontinence. The participants were trained in diary recording, and each diary was reviewed for completeness by trained research staff. We did not find a parallel difference between treatment groups in 24-hour changes in pad weight. Other trials conducted after our study have also reported a lack of correlation between changes in pad weight and diary-recorded frequency of incontinence, subjective measures of the severity of incontinence, and incontinence-specific quality of life, possibly because these techniques measure different domains of incontinence. 28,29 The generalizability of our findings might be limited by the facts that the participants were selected for their potential to adhere to the behavioral weightloss intervention and that participants with certain medical conditions were excluded. Since the participants were not blinded to their treatment assignment, differential reporting between the randomized groups cannot be excluded. The re- ductions in the frequency of incontinence in the control group were partially explained by a moderate effect of weight loss and physical activity, but we observed no evidence for a benefit from pelvic-floor exercises. Future studies might examine specifically whether weight loss combined with other incontinence interventions, such as pelvic-floor exercises, would be beneficial. Previous studies have indicated that behavioral weight-loss interventions can decrease the risk of type 2 diabetes 18,30 and hypertension, 31 improve control of hypertension 31,32 and hyperlipidemia, 32 and improve mood and quality of life. [33] [34] [35] Our results suggest that a decrease in urinary incontinence may be another benefit among the health improvements associated with moderate weight loss and support consideration of weight reduction as a first-line treatment for overweight and obese women with incontinence.
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